You just read:

Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016

News provided by

Daiichi Sankyo, Inc.

Aug 24, 2016, 08:00 ET